Summaries of published peptide research, framed for laboratory context.
Digestion destroys most peptides, which is why they are injected. BPC-157 is the exception researchers keep citing. Here is the structural reason for that, and an honest account of how thin the human evidence still is.
Tirzepatide hits two incretin receptors instead of one, and it does not hit them equally. Here is the pharmacology behind the imbalance, and what the SURPASS and SURMOUNT trials reported.
The triple agonist adds a third receptor to the GLP-1 template. Here is what the Phase 2 data reported, what the Phase 3 TRIUMPH trials are showing, and why it remains investigational.
What the GLP-1 class actually is, how single, dual, and triple receptor agonists differ, what the trials report, and where each compound stands on approval.
One targets a single receptor, one targets two, one targets three. Here is what the current research says about how they differ, and where each stands on approval.
This site is intended for qualified researchers. By continuing you confirm that you are 21 or over and that you are acquiring these compounds for laboratory research use only, not for human consumption. Full declaration.
